Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mitesh J Borad, MD
Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic , Scottsdale Arizona
Principal InvestigatorKOL profile → - Stephen Marcus, MD
ParinGenix Inc, Weston FL
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Scottsdale, Arizona, United States
- Disney Family Cancer Center
Burbank, California, United States
- Marin Cancer Care
Greenbrae, California, United States
- Scripps Clinic Torrey Pines ( Green Hospital)
La Jolla, California, United States
- Cleveland Clinic Florida
Weston, Florida, United States
- Loyola University Medical Center/cardinal Bernardin Cancer Center
Maywood, Illinois, United States
- Indiana University Health, Goshen Center for Cancer Care
Goshen, Indiana, United States
- Fesit-Weiller Cancer Center
Shreveport, Louisiana, United States
- Saint Mary'S Health Care
Grand Rapids, Michigan, United States
- Summa Health System - Cooper Cancer Center
Akron, Ohio, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Thomas Jefferson University [kimmel Cancer Center]
Philadelphia, Pennsylvania, United States
- Upmc Cancer Center
Pittsburgh, Pennsylvania, United States
- Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina, United States
- University of Texas Medical Branch
Galveston, Texas, United States
- South Texas Oncology & Hematology
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 31 Dec 2012
- Completion
- 30 Jun 2015
- Last update posted
- 6 Jun 2022
- Registered enrollment
- 60
- Registry id
- NCT01461915
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.